176
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome

ORCID Icon, , ORCID Icon, ORCID Icon &
Pages 3152-3159 | Received 29 Mar 2021, Accepted 30 May 2021, Published online: 25 Jun 2021
 

Abstract

Uric acid drives acute kidney injury in tumor lysis syndrome (TLS). This study investigated the relationship between uric acid and changes in estimated glomerular filtration rate (eGFR) in adults at risk for TLS. Linear regression was used to evaluate the relationship between uric acid area under the curve (AUC) and percent change in eGFR from baseline at hospital dismissal, 1 and 3 months. In 210 included participants, each 100 mg*hour/dL increase in 24 h AUC was associated with an average decline in eGFR at hospital dismissal of 9% (95%CI 3, 15) in univariate analysis. Each 100 mg*hour/dL increase in 24 h AUC was independently associated with an average decline in eGFR of 8% (95%CI 2, 13) at 1 month after dismissal. Additional research is needed to confirm these findings and determine whether treatments that reduce overall uric acid exposure improve kidney outcomes. Preserving kidney health could favorably impact cancer treatment eligibility, tolerability, and outcomes.

Disclosure statement

All authors declare no competing interest related to the content of this work. Dr. Erin Barreto is a consultant for FAST Biomedical (unrelated).

Additional information

Funding

This project was supported in part by CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Science (NCATS), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number K23AI143882 (PI; EFB) and the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG034676. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Health. This project was also supported, in part, by a small grant from the Mayo Midwest Pharmacy Research Committee.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.